Clinical trials: Disorder, Mood
Major Depressive Disorder
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect…
- Trial name
- NCT02279953
- Testing
- Vortioxetine 10-20 mg, SSRI
- Where
- 17 sites in Estonia, Finland and 3 more
- Volunteers
- 151 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorders, Mood Disorders
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Conditions
- Bipolar Disorders, Mood Disorders, Affective Disorders, Psychotic
- Trial name
- NCT00240721
- Testing
- topiramate
- Volunteers
- 363 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)
This study is designed to compare the efficacy of oral paroxetine 10 to 40 mg/day (initial dose:10 mg/day) versus placebo administered once daily (after evening meal) for 8 weeks in children and adolescents with major depressive…
- Trial name
- NCT00812812
- Testing
- paroxetine 10mg tablet, paroxetine 20mg tablet
- Where
- 33 sites in Japan
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients
The purpose of this study is to determine the initial (after 1-week of maintenance dosing) and extended (after 3-weeks of maintenance dosing) effect of topiramate, at doses up to 600 mg/day, on the steady-state pharmacokinetics…
- Trial name
- NCT00986128
- Testing
- topiramate
- Volunteers
- 32 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.
- Trial name
- NCT00036309
- Testing
- Duloxetine Hydrochloride
- Where
- United States
- Sponsor
- Eli Lilly and Company
Postpartum Depression
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
In this study, researchers will learn how postpartum depression symptoms may change after people first start taking zuranolone. This is a drug available for doctors to prescribe for people with postpartum depression, also known…
- Trial name
- NCT07398469
- Testing
- Zuranolone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Biogen
Major Depressive Disorder
A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.
- Trial name
- NCT00095745
- Testing
- Antidepressant + Aripiprazole
- Where
- 58 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder
Observational Study to Assess a 6-months Treatment With Gladem
Evaluation of a 6-months treatment with Gladem Experiences with the internet for performing a postmarketing study (PMS) trial
- Trial name
- NCT02231268
- Testing
- Gladem
- Volunteers
- 546 people
- Sponsor
- Boehringer Ingelheim
Bipolar Disorder
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania.
- Trial name
- NCT00488618
- Testing
- Cariprazine (RGH-188)
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Forest Laboratories
Depression, Bipolar
Olanzapine Treatment of Patients With Bipolar I Disorder
The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.
- Trial name
- NCT00510146
- Testing
- Olanzapine
- Where
- 16 sites in China, Japan and 1 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Bipolar Disorder
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
- Trial name
- NCT00216723
- Testing
- Aripiprazole
- Where
- 2 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder (MDD), Depression in Adults
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
- Conditions
- Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
- Trial name
- EMBRACE (NCT06793397)
- Testing
- CYB003, Psychological Support
- Where
- 79 sites in United States, Australia and 6 more
- Volunteers
- 330 people
- Sponsor
- Cybin IRL Limited
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an…
- Trial name
- NCT01145313
- Volunteers
- 501 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients…
- Trial name
- NCT00415142
- Testing
- saredutant (SR48968), escitalopram
- Where
- 8 sites in United States, Croatia and 6 more
- Volunteers
- 393 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
- Trial name
- NCT01741142
- Testing
- ABT-436, Escitalopram
- Where
- 18 sites in United States
- Volunteers
- 19 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Post Partum Depression
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).
- Trial name
- NCT03665038
- Testing
- Brexanolone
- Where
- 17 sites in United States
- Volunteers
- 28 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD)
AI-Supported Therapy for Depression and Anxiety Compared With Standard CBT
This study is a pivotal, randomised, controlled, non-inferiority trial evaluating "Nook," an AI-delivered, neurosymbolic, clinician-supervised digital psychological intervention for depression and anxiety, compared with standard…
- Trial name
- NCT07620340
- Testing
- AI-Digital CBT, Cognitive Behavioural Therapy
- Volunteers
- 400 people
- Sponsor
- PsyScale
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.